Homozygous Familial Hypercholesterolemia

Effective 01/29/2014
Revised 01/04/2018

Preferred Agents
Available with Clinical Edits

Non-Preferred Agents
Available with Clinical Edits
- Juxtapid®
- Kynamro®

Approval Criteria
- Diagnosis of Homozygous Familial Hypercholesterolemia (ICD-9 272.0) (ICD-10 E78.0)
- Trial and failure of High-Potency Statin therapy
  - Atorvastatin 80mg/day or
  - Rosuvastatin 40mg/day
- ADE/ADR to High-Potency Statin therapy
- LDL-C remains > 175

Denial Criteria
- Claims for patients under 18 years of age.
- Pregnancy
- Moderate or severe hepatic impairment (based on Child-Pugh category B or C) or with active liver disease, including unexplained persistent elevations of serum transaminases.
- Dosage exceeds FDA limitations
  - Juxtapid 60 mg/day
  - Kynamro 200 mg/wk
- Approval criteria not met
- Drug Prior Authorization Hotline: (800) 392-8030